Table 1 The results of the univariate analyses using two-sided stratifications
From: A combined index to classify prognostic comorbidity in candidates for radical prostatectomy
Category | Events | Hazard ratio | 95% CI | p | 10-year survival | 95% CI |
|---|---|---|---|---|---|---|
PSA < 10 ng/mL | 138/1165 | 1 | 87.3% | 84.7-89.4% | ||
PSA 10+ ng/mL or neoadjuvant therapy | 163/966 | 1.18 | 0.93-1.48 | 0.1665 | 83.5% | 80.5-86.0% |
Gleason score <8 | 198/1710 | 1 | 88.4% | 86.4-90.1% | ||
Gleason score 8-10 | 103/421 | 3.44 | 2.55-4.66 | <0.0001 | 72.5% | 66.7-77.4% |
organ confined | 168/1424 | 1 | 88.1% | 85.9-90.0% | ||
non confined | 133/707 | 1.64 | 1.29-2.09 | <0.0001 | 80.1% | 76.3-83.3% |
pN0 | 248/938 | 1 | 87.2% | 85.2-88.9% | ||
pN1 | 53/193 | 2.85 | 1.92-4.23 | <0.0001 | 67.9% | 59.2-75.1% |
ASA 1-2 | 218/1774 | 1 | 87.9% | 85.9-89.6% | ||
ASA 3 | 83/357 | 2.88 | 2.09-3.98 | <0.0001 | 73.3% | 67.2-78.4% |
Charlson score 0-1 | 220/1809 | 1 | 87.6% | 85.7-89.4% | ||
Charlson score 2+ | 81/322 | 3.18 | 2.28-4.43 | <0.0001 | 73.0% | 66.7-78.3% |
NYHA 0-1 | 270/2002 | 1 | 85.8% | 83.8-87.6% | ||
NYHA 2+ | 31/129 | 1.91 | 1.21-3.03 | 0.0059 | 79.2% | 70.4-85.7% |
CCS 0-1 | 268/2015 | 1 | 86.4% | 84.5-88.1% | ||
CCS 2+ | 33/116 | 2.85 | 1.74-4.67 | <0.0001 | 71.2% | 60.7-79.4% |
Disease count 0-1 | 145/1296 | 1 | 89.1% | 86.8-91.0% | ||
Disease count 2+ | 156/835 | 1.97 | 1.55-2.49 | <0.0001 | 79.7% | 76.2-82.8% |
No diabetes with end organ damage | 276/2034 | 1 | 86.2% | 84.3-87.9% | ||
Diabetes with end organ damage | 25/97 | 3.19 | 1.78-5.71 | 0.0001 | 68.3% | 55.2-78.3% |
Body mass index <30 kg/m2 | 237/1775 | 1 | 86.4% | 84.4-88.3% | ||
Body mass index 30+ kg/m2 | 64/356 | 1.69 | 1.22-2.32 | 0.0014 | 80.4% | 75.0-84.8% |